Corporate Banner
Satellite Banner
Proteomics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

GE Acquires Strategic Assets from Thermo

Published: Monday, January 06, 2014
Last Updated: Monday, January 06, 2014
Bookmark and Share
GE to acquire cell culture media and sera, gene modulation and magnetic beads businesses.

GE and Thermo Fisher Scientific announced that they have entered into an agreement for GE Healthcare to acquire Thermo Fisher’s HyClone™ cell culture media and sera, and gene modulation and magnetic beads businesses for approximately $1.06 billion.  The acquisition will allow GE to expand its offering of technologies for the discovery and manufacturing of innovative new medicines, vaccines and diagnostics in its growing Life Sciences business.  

The complementary product offerings and strong strategic fit of the acquired businesses will enable GE Healthcare to expand and accelerate the development of innovative “end-to-end” technologies for cell biology research, cell therapy and for the manufacture of innovative biological medicines and vaccines.  The acquisition is consistent with GE’s strategy to invest in high-technology, innovative businesses that deliver strong top-line growth and expanded margins. GE’s acquisition of the businesses, which is subject to regulatory approvals, is anticipated to close in the first part of 2014.  

GE Healthcare’s century of leadership in medical diagnostic technology includes its $4 billion Life Sciences business, which delivers innovative products and services for the fast-growing diagnostics, research and biopharmaceutical manufacturing sectors.

John Dineen, President and CEO, GE Healthcare said, “Life Sciences is one of our strongest and fastest-growing business areas, driven by the world’s demand for improved diagnostics and new, safer medicines.  Combining GE’s engineering expertise with our capabilities in life sciences is already bringing great benefits to industry, research and patients.  This deal makes a good business even better and will help us realize our vision of bringing better healthcare to more people at lower cost.”

Cell culture plays a key role in manufacturing medicines to treat diseases such as cancer and rheumatoid arthritis, as well as a new generation of vaccines.  Thermo Fisher’s well-respected HyClone™ cell culture media and sera products are highly complementary to GE Healthcare’s established technologies for cell biology research and biopharmaceutical manufacturing, enabling GE to offer its customers a substantially wider range of technologies and services.

GE Healthcare will also acquire Thermo Fisher’s gene modulation technologies, which strongly complement GE’s established technologies for drug discovery research, and the innovative Sera-Mag™ magnetic beads product line, which extends GE’s existing technologies in protein analysis and medical diagnostics.

Kieran Murphy, President and CEO of GE Healthcare’s Life Sciences division said, “We look forward to the HyClone cell culture and other businesses joining the GE family.  They are a great fit with our key areas of focus, and bring exciting new technologies, enhanced manufacturing capabilities as well as a great group of talented people to help grow our business.” 

“In addition to providing us with new approaches to drug discovery and biomedical research,” Murphy said, “this acquisition is a significant step forward for our customers in biopharmaceutical manufacturing.  They will benefit immediately from an expanded range of “start-to-finish” technologies that will help them improve product yields and reduce time-to-market. By expanding our production facilities to three continents, we will be able to offer the biopharmaceutical industry greater confidence in the security of supply of cell culture media and sera, a key part of their production process.”

The three acquired businesses generated combined annual revenues of approximately $250 million in 2013.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare Life Sciences and Promosome Sign Licensing Agreement
Innovative mammalian cell line development technologies that show promise for increasing manufacturing efficiency of vital biopharmaceuticals.
Tuesday, April 29, 2014
GE Healthcare to acquire Xcellerex Inc.
Addition of high growth company builds integrated, start-to-finish industry offering, focused on lowering costs, increasing productivity and reducing time to market.
Thursday, March 08, 2012
GE Healthcare Executes Recombinant Protein L License from Affitech
Company agrees to pay a royalty of the net sales of all related products to Affitech.
Tuesday, October 18, 2011
GE Healthcare to Invest $1 Billion in New Oncology Solutions
Expanding advanced cancer diagnostic and molecular imaging capabilities.
Saturday, September 17, 2011
GE Healthcare Appoints Kieran Murphy as Life Sciences CEO, Successor to Peter Ehrenheim
On 1 April 2011, Kieran Murphy will be promoted to succeed current Life Sciences President and CEO Peter Ehrenheim who will retire from GE after a transition period on July 31 2011.
Tuesday, February 22, 2011
GE Healthcare to Host DiPIA 2010 - Developments in Protein Interaction Analysis
Addressing functional characterization of proteins and their interactions.
Thursday, July 22, 2010
GE Healthcare to Host ‘Current Trends in Microcalorimetry and Biacore Symposium’
The symposium addressing functional characterization of biomolecular stability and interactions.
Monday, June 22, 2009
GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences
Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare.
Thursday, June 04, 2009
GE Healthcare Forms Strategic Alliance with FUJIFILM in Life Sciences
GE Healthcare announced that it has entered into a Strategic Alliance Agreement with FUJIFILM Corporation. Under the alliance, Fujifilm will develop, manufacture and supply advanced biomolecular imaging systems to GE Healthcare.
Thursday, May 28, 2009
Celestial Biologicals and GE Healthcare Collaborates to Set up Plasma Fractionation Facility in India
The collaboration will include technology, products, processes and project development for establishing chromatography-based plasma fractionation facility.
Friday, January 23, 2009
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Cell Cargo Ships in Near Future?
Virus-inspired container design may lead to cell cargo ships following construction of ten large, two-component, icosahedral protein complexes.
Protein Reinforces Growth of Damaged Muscles
Biologists have found a protein involved in stem cells that bolsters damaged muscle tissue growth - potential for muscle degeneration treatments.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
New Protein Model Could Accelerate Drug Development
Stony Brook-led international research team creates ultra-fast approach to model protein interactions.
Researchers Can Control Genes Involved in Cancer
A new way to control the activity of a protein, that is often upregulated in cancer, has been discovered by Moffitt researchers through monoubiquitination mechanism.
Mitochondrial Role in Metastatic Cancer
Researchers have manipulated proteins, sourced from tumour cells, that are essential for maintaining tumour cells and in doing so, have significantly reduced the ability of cancer cells.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
Scientists Culture Elusive Yellowstone Microbe
ORNL scientists have successfully isolated and cultured a Yellowstone sourced acidic hot-spring based microbe.
Seeing RNA at the Nanoscale
MIT researchers have developed a new way to image proteins and RNA inside neurons of brain tissue.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!